Clinical Trial Update: Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE) [Phase 3]

View source ↗

Summary

Phase III study of BAY43-9006 (sorafenib) in patients with advanced hepatocellular carcinoma after transcatheter arterial chemoembolization has completed, with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: Bayer | Conditions: Carcinoma, Hepatocellular | Phase 3 | Status: COMPLETED | Results posted: 2011-01-20